P

Prisma Health | Upstate Greenville Memorial Cardiac Research

Research site
(Unclaimed)
Location
701 Grove Road, Greenville, South Carolina, United States of America

Site insights

Top conditions

Top treatments

Lenalidomide
nivolumab
mFOLFOX
SHR-A1904
ONC-392
STRO-002
ABBV-400
Folate
Epcoritamab
bendamustine

Parent organization

This site is a part of Prisma Health

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 23 total trials

(HALT) Embrace Hydrogel Embolic System (HES) Study of Embolization in Peripheral Arterial Bleeds

To evaluate the safety and effectiveness of Embrace Hydrogel Embolic System for the transcatheter embolization of peripheral arterial bleeds.

Enrolling
Arterial Bleeding in Solid Organs and Peripheral Arteries
Device: Embrace HES including Instylla™ Delivery Kit and Instylla™ Microcatheter

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicul...

Enrolling
Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab

The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, a...

Enrolling
Advanced Solid Tumors
Drug: SHR-A1904

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Rituximab
Drug: Lenalidomide

The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic...

Enrolling
Subdural Hematoma
Device: Surgical Management + Treatment
Device: Treatment

The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Exc...

Enrolling
Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Abdominal Aortic Aneurysm
Device: Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Device: Medtronic Endurant II or Endurant IIs Stent Graft System

The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromod...

Active, not recruiting
Overactive Bladder
Device: Medtronic Implantable Tibial Neuromodulation (TNM) System

This trial is being conducted in order to compare angiographic outcomes in patients receiving 0.014-0.0155" platinum framing and filling coils (large...

Active, not recruiting
Cerebral Aneurysm
Procedure: Coil Embolization with larger Diameter Coils
Procedure: Coil Embolization with Standard Diameter Coils

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5...

Enrolling
Abdominal Aortic Aneurysm
Drug: Nectero EAST System

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), opt...

Enrolling
Advanced Non-Small Cell Squamous Lung Cancer
Epidermal Growth Factor Receptor C797S
Drug: BDTX-1535 monotherapy

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refracto...

Enrolling
AML
Leukemia, Myeloid, Acute
Drug: Gilteritinib
Biological: Granulocyte colony-stimulating factor

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 m...

Enrolling
Salivary Gland Cancer
Adenoid Cystic Carcinoma
Drug: Docetaxel
Drug: Pembrolizumab

A multicenter, interventional, feasibility comparison with historical controls

Active, not recruiting
Moderate to High-risk Noncardiac Surgery
Device: Acumen HPI Smart Alerts and Smart Trends Software

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Active, not recruiting
Endometrioid Adenocarcinoma
Endometrial Cancer
Drug: STRO-002

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is in...

Enrolling
Follicular Lymphoma (FL)
Drug: Obinutuzumab
Drug: Rituximab
Locations recently updated

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events...

Enrolling
Hepatocellular Carcinoma
Esophageal Squamous Cell Carcinoma
Drug: ABBV-400

Trial sponsors

Arcus Biosciences logo
Genmab logo
Medtronic logo
Seagen logo
AbbVie logo
B
Covidien logo
Edwards Lifesciences logo
Hengrui Medicine logo
Indivior logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems